Persistent gaps in glycaemic and cardio-renal control continue to fuel excess morbidity in diabetes. Emerging data show that real-time digital biomarkers from continuous glucose monitoring (CGM) and adaptive automated insulin-delivery (AID) algorithms can individualise therapy, expand time-in-range and blunt downstream cardiovascular and renal risk—well beyond what HbA1c-centred care achieves.

This 60-minute symposium—streamed live on 6 December 2024 as part of the Virtual CVOT Summit 2024—gathers international experts to translate the latest evidence on CGM metrics, exercise-aware AID systems and their integration with guideline-directed pharmacological pillars. Attendees will learn practical strategies to harness technology-driven insights for safer glucose control, fewer hypoglycaemic events and improved long-term cardio-renal outcomes in both type 1 and type 2 diabetes.